|
|
|
|
Frost & Sullivan: Will Big Pharma Embrace its Orphans?
- While most big pharmaceutical and biotechnology companies have traditionally depended on blockbuster molecules, it is estimated that $90.0 billion worth of ethical molecules will come off patent during 2007-2012.The industry is...
|
|
|
ASHG 2008: Gaucher Disease Mutation Carriers at Higher Risk for Parkinson's Disease
_ ASHG 2008: Gaucher Disease Mutation Carriers at Higher Risk for Parkinson's Disease.
|
|
|
Will Big Pharma Embrace Its Orphans?
While most big pharmaceutical and biotechnology companies have traditionally depended on blockbuster molecules, it is estimated that $90.0B worth of ethical molecules will come off patent during 2007-2012.The industry is therefore...
|
|
|
Will Big Pharma Embrace Its Orphans?
/PRNewswire/ -- While most big pharmaceutical and biotechnology companies have traditionally depended on blockbuster molecules, it is estimated that $90.0 billion worth of ethical molecules will come off patent during 2007-2012.The...
|
|
|
Will Big Pharma Embrace Its Orphans?
/PRNewswire/ -- While most big pharmaceutical and biotechnology companies have traditionally depended on blockbuster molecules, it is estimated that $90.0 billion worth of ethical molecules will come off patent during 2007-2012.The...
|
|
|
Eight-year Clinical Outcomes Of Enzyme Replacement Therapy In 884 Children With Type I Gaucher Disease
ScienceDaily (Nov.16, 2008) Gaucher disease is a rare genetic disorder that occurs when a person lacks an enzyme called glucocerebrosidase. The most common form of this disorder is type 1 Gaucher disease. Type 1 Gaucher...
|
|
|
Will Big Pharma Embrace Its Orphans?
LONDON, Nov.17 /PRNewswire/ -- While most big pharmaceutical and biotechnology companies have traditionally depended on blockbuster molecules, it is estimated that $90.0 billion worth of ethical molecules will come off patent during 2007...
|
|
|
Will Big Pharma Embrace Its Orphans?
LONDON, Nov.17 /PRNewswire/ -- While most big pharmaceutical and biotechnology companies have traditionally depended on blockbuster molecules, it is estimated that $90.0 billion worth of ethical molecules will come off patent during 2007...
|
|
|
Will Big Pharma Embrace Its Orphans?
LONDON, Nov.17 /PRNewswire/ -- While most big pharmaceutical and biotechnology companies have traditionally depended on blockbuster molecules, it is estimated that $90.0 billion worth of ethical molecules will come off patent during 2007...
|
|
|
Will Big Pharma Embrace Its Orphans?
LONDON, Nov.17 /PRNewswire/ -- While most big pharmaceutical and biotechnology companies have traditionally depended on blockbuster molecules, it is estimated that $90.0 billion Orphan drugs are intended for the prevention and treatment...
|
|
|
Will Big Pharma Embrace Its Orphans?
LONDON, Nov.17 /PRNewswire/ -- While most big pharmaceutical and biotechnology companies have traditionally depended on blockbuster molecules, it is estimated that $90.0 billion worth of ethical molecules will come off patent during 2007...
|
|
|
Will Big Pharma Embrace Its Orphans?
LONDON, Nov.17 /PRNewswire/ -- While most big pharmaceutical and biotechnology companies have traditionally depended on blockbuster molecules, it is estimated that $90.0 billion worth of ethical molecules will come off patent during 2007...
|
|
|
Will Big Pharma Embrace Its Orphans?
LONDON, Nov.17 /PRNewswire/ -- While most big pharmaceutical and biotechnology companies have traditionally depended on blockbuster molecules, it is estimated that $90.0 billion worth of ethical molecules will come off patent during 2007...
|
|
|
Will Big Pharma Embrace Its Orphans?
/PRNewswire via COMTEX/ -- FRSU | Quote | Chart | News | PowerRating -- While most big pharmaceutical and biotechnology companies have traditionally depended on blockbuster molecules, it is estimated that $90.0 billion worth of ethical...
|
|
|
Will Big Pharma Embrace Its Orphans?
/PRNewswire via COMTEX/ -- While most big pharmaceutical and biotechnology companies have traditionally depended on blockbuster molecules, it is estimated that $90.0 billion worth of ethical molecules will come off patent during 2007-2012.
|
|
|
Will Big Pharma Embrace Its Orphans?
LONDON, Nov.17 /PRNewswire/ -- While most big pharmaceutical and biotechnology companies have traditionally depended on blockbuster molecules, it is estimated that $90.0 billion worth of ethical molecules will come off patent during 2007...
|
|
|
Will Big Pharma Embrace Its Orphans?
LONDON, Nov.17 /PRNewswire/ -- While most big pharmaceutical and biotechnology companies have traditionally depended on blockbuster molecules, it is estimated that $90.0 billion worth of ethical molecules will come off patent during 2007...
|
|
|
Will Big Pharma Embrace Its Orphans?
LONDON, Nov.17 /PRNewswire/ -- While most big pharmaceutical and biotechnology companies have traditionally depended on blockbuster molecules, it is estimated that $90.0 billion worth of ethical molecules will come off patent during 2007...
|
|
|
Will Big Pharma Embrace Its Orphans?
Orphan drugs are intended for the prevention and treatment of very serious rare diseases such as chronic myeloid leukaemia, pulmonary arterial hypertension, gaucher disease and adrenal cortical carcinoma.Frost & Sullivan (http:/...
|
|
|
Will Big Pharma Embrace Its Orphans?
LONDON, Nov.17 /PRNewswire/ -- While most big pharmaceutical and biotechnology companies have traditionally depended on blockbuster molecules, it is estimated that $90.0 billion worth of ethical molecules will come off patent during 2007...
|
|
|
Will Big Pharma Embrace Its Orphans?
LONDON, Nov.17 /PRNewswire/ -- While most big pharmaceutical and biotechnology companies have traditionally depended on blockbuster molecules, it is estimated that $90.0 billion worth of ethical molecules will come off patent during 2007...
|
|
|
Will Big Pharma Embrace Its Orphans?
LONDON, Nov.17 /PRNewswire/ -- While most big pharmaceutical and biotechnology companies have traditionally depended on blockbuster molecules, it is estimated that $90.0 billion worth of ethical molecules will come off patent during 2007...
|
|
|
Will Big Pharma Embrace Its Orphans?
LONDON, Nov.17 /PRNewswire/ -- While most big pharmaceutical and biotechnology companies have traditionally depended on blockbuster molecules, it is estimated that $90.0 billion worth of ethical molecules will come off patent during 2007...
|
|
|
Will Big Pharma Embrace Its Orphans?
LONDON, Nov.17 /PRNewswire/ -- While most big pharmaceutical and biotechnology companies have traditionally depended on blockbuster molecules, it is estimated that $90.0 billion worth of ethical molecules will come off patent during 2007...
|
|
|
Will Big Pharma Embrace Its Orphans?
LONDON, Nov.17 /PRNewswire/ -- While most big pharmaceutical and biotechnology companies have traditionally depended on blockbuster molecules, it is estimated that $90.0 billion worth of ethical molecules will come off patent during 2007...
|
